More than a dozen fish oil-based COVID-19 treatments are racing towards production

0
90

Projects around the world seek to develop successful prevention methods or treatments for COVID-19 as the government-sponsored pharmaceutical companies advance the development of a vaccine against the virus that has claimed nearly 790,000 lives worldwide and disrupted economies around the world. These potential treatments include omega-3 fatty acids, which have shown promise as therapeutic agents in previous studies.

The Global Organization for EPA and DHA (GOED) is aware of 14 clinical studies that are currently investigating the use of EPA and DHA oils.

A promising formulation based on fish oil is being developed in collaboration between KD Pharma and SLA Pharma.

In a study conducted by both companies, patients who have contracted coronavirus are given pills to minimize symptoms and reduce the risk of complications that lead to serious consequences such as the need for artificial respiration.

Clinical trial results could be available by the end of next month, a project spokesperson recently told IntraFish.

Norwegian biotech company Hofseth BioCare has now conducted phase 2 clinical trials to evaluate the ability of its OmeGo salmon oil to reduce COVID-19-related acute respiratory distress syndrome (ARDS).

Treatment focuses on ex-smokers and steroid-resistant asthma patients who have lung injuries caused by COVID-19.

Omega-3 wound care products maker, Kerecis, and the National Hospital of Iceland are partnering to evaluate the effectiveness of Kerecis’ Omega3 viral drug system in COVID-19 patients.

The unauthorized use of an approved drug is often referred to as “off-label” use. This may mean the drug is being used for a disease or medical condition that it is not approved to treat, such as: For example, if chemotherapy is approved to treat one type of cancer but healthcare providers are using it to treat another type of cancer.

Doctors in Italy are already using the product off-label, spraying it in the mouth and nasal cavities of patients who are early on with COVID-19.

Japanese-owned Pharmavite in Japan plans to provide nutritional supplements to the Icahn School of Medicine at Mount Sinai in New York to determine if EPA and DHA have an impact on odor loss in COVID-19 patients.

Amarin and Kaiser Permanente’s MITIGATE COVID-19 study examines the effects of Vascepa on morbidity and mortality associated with COVID-19 and other upper respiratory tract viral infections (URIs) in a high-risk group of adults suffering from atherosclerotic heart disease Circulatory Disease (ASCVD).

Amarin is also conducting a study, supported by the Canadian Medical and Surgical Knowledge Translation Research Group, of the effects of twice-daily doses of Vascepa on key markers of inflammation in COVID-19 patients.

Tests from Harvard University, the Cardiovascular Institute of Rosario, and the Latin American Clinical Trials in Argentina aim to investigate whether eight grams of EPA daily increases the risk of COVID-19 in 1,500 Argentine healthcare workers as part of the PREPARE-IT study program at Sept. Lower percent.

There is a fair share of court hearings in the Middle East region.

In Jordan, the country’s Applied Science Private University is testing whether 300 mg of EPA and DHA, given to uninfected test subjects for two months, significantly affect their interleukin levels compared to the control group.

At the same time, the Sabzevar University of Medical Sciences in Iran is investigating whether omega-3 supplementation improves inflammatory and biochemical markers in critically ill COVID-19 patients.

This is because King Saud University in Saudi Arabia is studying the effects of Abbott’s Oxepa supplement, which includes EPA, on the disease.

Bahia State University in northeast Brazil is studying the effects of daily supplementation with L-arginine, nucleotides, and omega-3 fatty acids on the inflammatory response in COVID-19 patients.

Scientists at Karolinska University Hospital in Sweden are investigating whether supplementing an Omegaven intravenous fish oil emulsion can resolve inflammatory storms in COVID-19 patients.

Groupe Hospitalier Paris Saint Joseph is investigating whether eicosanoid levels measured at different stages of COVID-19 infection can provide a prognosis for the disease.

Further south and in Spain, researchers at Vall Hebron University in Barcelona are trying to find out whether parenteral fish oil is effective at reducing liver dysfunction in COVID-19 patients.

Despite this prospective prevention and treatment, science does not support the claim that consuming omega-3-rich products boosts immunity to coronavirus, according to GOED.

LEAVE A REPLY

Please enter your comment!
Please enter your name here